“Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s124. doi:10.25251/skin.4.supp.124.